EUVIMEDEUVIMED entdecken
LeitlinieSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Evidence-based clinical practice guidelines for pediatric hepatoblastoma: a systematic review and expert recommendations from Korea

Jin Kyung Suh, Jisun Hwang, Hee Mang Yoon, Kyong Ihn, Jung-Man Namgoong, Jeong A Park, Jung-Sun Kim, Hyoung Soo Choi, Sung Hye Park, Dong Ah Park, Kyung-Nam Koh

Clinical and Experimental Pediatrics · 15.11.2026 · 69 (11) · 912-924

DOI: 10.3345/cep.2026.02691 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical and Experimental Pediatrics, erschienen am 15.11.2026. Verfasst von Jin Kyung Suh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatoblastoma (HB) is the most common primary liver malignancy in children, predominantly affecting those younger than 3 years of age. Although the overall survival rate has improved significantly over the past few decades, standardized clinical practice guidelines for HB in Korea have been lacking. This clinical practice guideline was developed to provide evidence-based recommendations for the diagnosis and treatment of HB in children. A multidisciplinary working group comprising pediatric hematologists/oncologists, radiologists, surgeons, pathologists, and methodologists systematically reviewed the literature published up to May 2023. For pretreatment imaging, both abdominal computed tomography and magnetic resonance imaging are useful for PRE-Treatment EXTent of disease (PRETEXT) staging, with each modality offering distinct advantages. PRETEXT staging at diagnosis is recommended as it provides valuable prognostic information. For standard-risk HB (PRETEXT I–III without metastasis and alpha-fetoprotein ≥100 ng/mL), cisplatinbased chemotherapy without doxorubicin is recommended over cisplatin-doxorubicin combination therapy, as it demonstrates equivalent survival outcomes with fewer adverse effects. In carefully selected patients who are eligible for complete resection at diagnosis, upfront surgery without neoadjuvant chemotherapy should be considered to spare unnecessary chemotherapy and its toxicities. For patients with residual pulmonary metastases after chemotherapy, pulmonary metastasectomy should be considered. Sodium thiosulfate administration following cisplatin should be considered to reduce ototoxicity, although the supporting evidence is derived predominantly from standard-risk patients and its availability in Korea remains limited. Regarding histological subtypes, well-differentiated fetal HB is associated with favorable outcomes and may be treated with surgery alone, whereas the small cell undifferentiated pattern is no longer classified as a HB subtype and requires immunohistochemical and molecular testing to distinguish it from malignant rhabdoid tumor and other small round cell tumors. This guideline represents the first evidence-based clinical practice guideline for pediatric HB in Korea. It aims to standardize the diagnostic and therapeutic approaches, ultimately improving outcomes for Korean children with HB. Given the rarity of this tumor, international collaboration and prospective data collection remain essential for future guideline updates.

Schlagwörter

Stichwörter der Autor:innen

ChildDrug therapyHepatoblastomaPractice guidelinePrognosis

Autor:innen und Institutionen

  • Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Division of Pediatric Surgery, Severance Children's Hospital, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Pediatric Surgery, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Pediatrics, Inha University Hospital, Incheon, Korea.
  • Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Förderung

  • National Cancer Center

Zitieren

APA

Suh, J. K., Hwang, J., Yoon, H. M., Ihn, K., Namgoong, J. M., Park, J. A., Kim, J. S., Choi, H. S., Park, S. H., Park, D. A., & Koh, K. N. (2026). Evidence-based clinical practice guidelines for pediatric hepatoblastoma: a systematic review and expert recommendations from Korea. Clinical and Experimental Pediatrics, 69(11), 912-924. https://doi.org/10.3345/cep.2026.02691

Vancouver

Suh JK, Hwang J, Yoon HM, Ihn K, Namgoong JM, Park JA, et al. Evidence-based clinical practice guidelines for pediatric hepatoblastoma: a systematic review and expert recommendations from Korea. Clinical and Experimental Pediatrics. 2026;69(11):912-924. doi:10.3345/cep.2026.02691

BibTeX
@article{Suh2026,
  author = {Suh, Jin Kyung and Hwang, Jisun and Yoon, Hee Mang and Ihn, Kyong and Namgoong, Jung-Man and Park, Jeong A and Kim, Jung-Sun and Choi, Hyoung Soo and Park, Sung Hye and Park, Dong Ah and Koh, Kyung-Nam},
  title = {Evidence-based clinical practice guidelines for pediatric hepatoblastoma: a systematic review and expert recommendations from Korea},
  journal = {Clinical and Experimental Pediatrics},
  year = {2026},
  volume = {69},
  number = {11},
  pages = {912--924},
  doi = {10.3345/cep.2026.02691}
}
Kostenlos starten →